Pamiparib

Phase 3Small molecule

Pamiparib is used to treat certain types of cancer, particularly ovarian cancer, by blocking a protein that helps cancer cells repair DNA damage. It works best in patients whose cancer cells have specific genetic mutations (BRCA mutations).[1] Pamiparib is currently being investigated across 7 indications[3], with its most advanced program in Phase 3.[1]

Pamiparib is one of 243 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

242

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerUnknown status

Advanced MalignanciesEnrolling by invitation

TreatmentNot yet recruiting

Head and Neck CancerRecruiting

Newly DiagnosedActive, not recruiting

Refractory Solid TumorsActive, not recruiting

Ovarian CancerActive, not recruiting

Prostate CancerPhase 2

Unknown status

Advanced MalignanciesPhase 3

Enrolling by invitation

TreatmentPhase 2

Not yet recruiting

Head and Neck CancerPhase 1

Recruiting

Newly DiagnosedPhase 1

Active, not recruiting

Refractory Solid TumorsPhase 1

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Pamiparib

BeiGene

Phase 3

1 2

Biltricide

Bayer

Preclinical

4 3

Dexilant

Takeda

Preclinical

2 4

Niclocide

Bayer

Preclinical

1 5

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 6

Valium

Akero Therapeutics

Preclinical

2 7

Lotemax

PPharmos

Preclinical

1 8

Norpramin

VValidus Pharmaceuticals

Preclinical

1 9

Clomid

Ferring

Preclinical

1 10

Aurlumyn

BBTG International Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Ovarian Cancer

NCT03519230

Q1 2028

Phase 1Recruiting

Head and Neck Cancer

NCT05526924

Q2 2029

Phase 2Recruiting

Prostate Cancer

NCT06387056

Q4 2029

Phase 2Not yet recruiting

Treatment

NCT06692491

Clinical

Trials by Indication[1]

Ovarian Cancer5 trials

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Active, not recruiting· BeiGene logo

BeiGene·Phase 3·NCT03519230·224 enrolled

A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT05489926·15 enrolled

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Completed·SSun Yat-sen University·Phase 1/2·NCT05494580·29 enrolled

Show 2 more trials

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Active, not recruiting·BBai-Rong Xia·Phase 2·NCT05652283·37 enrolled

Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer

Completed·TTongji Hospital·Phase 2·NCT05044871·108 enrolled

Prostate Cancer3 trials

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Terminated· BeiGene logo

BeiGene·Phase 2·NCT03712930·13 enrolled

A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer

Unknown status·HHongqian Guo·Phase 2·NCT05376722·30 enrolled

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

Recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT06387056·40 enrolled

Advanced Solid Tumors2 trials

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Completed· BeiGene logo

BeiGene·Phase 1·NCT02660034·229 enrolled

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

Completed· BeiGene logo

BeiGene·Phase 1/2·NCT03333915·128 enrolled

Head and Neck Cancer1 trial

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Recruiting·UUniversity of Chicago·Phase 1·NCT05526924·30 enrolled

Newly Diagnosed1 trial

Study of Pamiparib in Newly Diagnosed and rGBM

Active, not recruiting·NNader Sanai·Phase 1·NCT04614909·45 enrolled

13 more indications

Refractory Solid Tumors1 trial

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05038839·44 enrolled

BRCA1/2 Mutation1 trial

Pamiparib in mCRPC With HRD or BRCA1/2 Mutation

Unknown status·SSun Yat-sen University·Phase 2·NCT05327621·50 enrolled

Tislelizumab1 trial

A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects

Unknown status·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT04985721·60 enrolled

Biliary Tract Cancer1 trial

Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer

Withdrawn·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT04796454

Advanced Malignancies1 trial

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Enrolling by invitation·BBeOne Medicines·Phase 3·NCT04164199·430 enrolled

Treatment1 trial

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

Not yet recruiting·PPeking University Shenzhen Hospital·Phase 2·NCT06692491·200 enrolled

Carcinosarcoma1 trial

Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy

Withdrawn·AAustralia New Zealand Gynaecological Oncology Group·Phase 2·NCT03933761

Concurrent Chemoradiotherapy1 trial

Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy

Unknown status·FFudan University·Phase 2·NCT05483543·44 enrolled

Cancer1 trial

Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer

Completed· BeiGene logo

BeiGene·Phase 1·NCT03994211·25 enrolled

Leiomyoma1 trial

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 2·NCT04603365

Glioblastoma1 trial

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

Completed·BBeiGene USA, Inc.·Phase 1/2·NCT03150862·116 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Completed· BeiGene logo

BeiGene·Phase 1·NCT03150810·139 enrolled

Gastric Cancer1 trial

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Completed· BeiGene logo

BeiGene·Phase 2·NCT03427814·136 enrolled

Sources

References

[1]
ClinicalTrials.gov — 25 trial records for Pamiparib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pamiparib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pamiparib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeiGene company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Poly [ADP-Ribose] Polymerase 2 Inhibitor; Poly [ADP-Ribose] Polymerase-1 Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BeiGene

Pamiparib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Q2 2029

Q4 2029

Trials by Indication[1]

Ovarian Cancer5 trials

Prostate Cancer3 trials

Advanced Solid Tumors2 trials

Head and Neck Cancer1 trial

Newly Diagnosed1 trial

Refractory Solid Tumors1 trial

BRCA1/2 Mutation1 trial

Tislelizumab1 trial

Biliary Tract Cancer1 trial

Advanced Malignancies1 trial

Treatment1 trial

Carcinosarcoma1 trial

Concurrent Chemoradiotherapy1 trial

Cancer1 trial

Leiomyoma1 trial

Glioblastoma1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Gastric Cancer1 trial

References

Drug Info

Quick Facts

Related News